Research in the Context of a Pandemic
- 25 February 2021
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 384 (8) , 755-757
Abstract
The current literature on the treatment of coronavirus disease 2019 (Covid-19) is filled with anecdotal reports of therapeutic successes in clinical trials with small numbers of patients and observational cohort studies claiming efficacy with little regard to the effect of unrecognized confounders. For the field to move forward and for patients’ outcomes to improve, there will need to be fewer small or inconclusive studies and more studies such as the dexamethasone trial now reported by the RECOVERY Collaborative Group1 in the Journal.Keywords
This publication has 5 references indexed in Scilit:
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)JAMA, 2020
- A Randomized, Controlled Trial of Ebola Virus Disease TherapeuticsNew England Journal of Medicine, 2019
- Large-scale randomized evidence: Large, simple trials and overviews of trialsJournal of Clinical Epidemiology, 1995